Successful treatment of severe pemphigus vulgaris with reduced side effects using a novel IVIg preparation

• Verfasst von: Wiedenmayer, Nadine [VerfasserIn]
• Verfasst von: Vollmer, Anastasia S. [VerfasserIn]
• Verfasst von: Winkler, Julia K. [VerfasserIn]
• Verfasst von: Enk, Alexander [VerfasserIn]
• Titel: Successful treatment of severe pemphigus vulgaris with reduced side effects using a novel IVIg preparation
• Verf.angabe: Nadine Wiedenmayer, Anastasia S. Vollmer, Julia K. Winkler, Alexander H. Enk
• E-Jahr: 2024
• Jahr: 12 June 2024
• Umfang: 6 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 14.11.2024
• Titel Quelle: Enthalten in: Dermatology and therapy
• Ort Quelle: Heidelberg : Springer, 2011
• Jahr Quelle: 2024
• Band/Heft Quelle: 14(2024), 7, Seite 1969-1974
• ISSN Quelle: 2190-9172
• DOI: doi:10.1007/s13555-024-01191-3
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Autoimmune disease
• Sach-SW: High-dose intravenous immunoglobulins
• Sach-SW: IVIg
• Sach-SW: Pemphigus vulgaris
• Sach-SW: Side effects
• K10plus-PPN: 1908547804

Abstract

Pemphigus vulgaris (PV) is a rare autoimmune bullous dermatosis (AIBD) characterized by painful blistering of the skin and mucosa caused by autoantibodies that lead to loss of adhesion in the epidermis. Standard therapy for PV is corticosteroids, either alone or in combination with steroid-sparing immunosuppressants or infusions with rituximab. According to the published European guideline, high-dose intravenous immunoglobulin (IVIg) therapy with a dosage of 2 g per kg body weight distributed over 2-5 days every 4 weeks is a promising treatment option, especially for severe or refractory disease. This report describes a 73-year-old female patient with severe and recurrent disease who achieved stabilization with IVIg treatment. However, the patient experienced side effects such as headaches, nausea, and vomiting, which affected daily life. Hence, she was transitioned to a new IVIg preparation with a new manufacturing process, resulting in fewer side effects and an improved quality of life. Further follow-up is necessary to fully evaluate the effectiveness and tolerability of this new IVIg product.